Notably, tumor-specific neoantigens encoded by KRAS mutations have been identified as highly immunogenic targets for precision cancer vaccines to enhance antitumor immunity, with encouraging preclinical and clinical outcomes [32, 33]. This evidence concerns the gene KRAS and cancer.